Jiangxi Synergy Pharmaceutical is an API manufacturer based in China. It holds 20 active US drug master files across a filed portfolio of 20 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 August 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3008465739 |
| Molecule | Regulators | Docs |
|---|---|---|
| Gabapentin | SFDA (Saudi Arabia), US FDA | 4 |
| Celecoxib | SFDA (Saudi Arabia), US FDA | 3 |
| Azilsartan Medoxomil | US FDA | 2 |
| Edoxaban | SFDA (Saudi Arabia), US FDA | 2 |
| Empagliflozin | SFDA (Saudi Arabia), US FDA | 2 |
| Vildagliptin | SFDA (Saudi Arabia), US FDA | 2 |
| Vonoprazan | SFDA (Saudi Arabia), US FDA | 2 |
| Apixaban | US FDA | 1 |
| Canagliflozin | US FDA | 1 |
| Crisaborole | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Dapagliflozin | US FDA | 1 |
| Febuxostat | US FDA | 1 |
| Mirabegron | US FDA | 1 |
| Mirabegron Α | SFDA (Saudi Arabia) | 1 |
| Opicapone | US FDA | 1 |
| Rabeprazole | SFDA (Saudi Arabia) | 1 |
| Rivaroxaban | US FDA | 1 |
| Roxadustat | US FDA | 1 |
| Ticagrelor | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 4 | None |
| US FDA | None | 1 |
Choose your molecules and target markets. Jiangxi Synergy Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free